Klotz Laurence, Andriole Gerald, Cash Hannes, Cooperberg Matthew, Crawford E David, Emberton Mark, Gomez-Sancha Fernando, Klein Eric, Lughezzani Giovanni, Marks Leonard, Montorsi Francesco, Salomon Georg, Sanchez-Salas Rafael, Shore Neal, Taneja Samir
Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Canada.
Urologic Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, USA.
Contemp Clin Trials. 2022 Jan;112:106618. doi: 10.1016/j.cct.2021.106618. Epub 2021 Nov 1.
Micro-ultrasound (microUS) is a novel ultrasound-based imaging modality which has demonstrated the ability to visualize prostate cancer. Multiparametric MRI/ultrasound (mpMRI/US) fusion has recognized advantages for the performance of prostate biopsy, however, it encompasses additional cost, time and technical expertise to performing prostate biopsy in comparison to conventional trans-rectal ultrasound biopsy. MicroUS may simplify and optimize this pathway.
OPTIMUM is a 3-arm randomized controlled trial comparing microUS guided biopsy with MRI/US fusion and MRI/MicroUS "contour-less" fusion. This trial will investigate whether microUS alone, or in combination with mpMRI, provides effective guidance during prostate biopsy for the detection of clinically significant prostate cancer (csPCa) for biopsy naïve subjects. 1200 subjects will be randomized. The economic impact will be evaluated.
The rate of csPCa (defined as Grade Group 2 and above) in each arm will be compared. The primary hypothesis is non-inferiority of csPCa rate between the MRI/US fusion arm and the microUS-only arm (including the blinded microUS-only portion of the MRI/MicroUS arm). As a secondary objective, the csPCa rate between MRI/MicroUS fusion and MRI/US fusion arms will also be compared. Other secondary objectives include the increase in rate of patients diagnosed with csPCa due to each type of sample (mpMRI targeted, microUS targeted, systematic), the negative predictive value of each imaging modality, and a health economic analysis of the procedures in each arm.
OPTIMUM will determine whether microUS can be used as an alternative to MRI/US fusion biopsy. The trial will also evaluate the efficacy of the simplified "contour-less" MRI/MicroUS fusion procedure. The adoption of the microUS technique will increase the proportion of men who can benefit from modern imaging-centric diagnostic strategies, and may help reduce variability, complexity, waiting time and cost within the diagnostic pathway.
微型超声(microUS)是一种基于超声的新型成像模式,已证明其能够可视化前列腺癌。多参数磁共振成像/超声(mpMRI/US)融合在前列腺活检操作方面具有公认的优势,然而,与传统经直肠超声活检相比,它在进行前列腺活检时需要额外的成本、时间和技术专长。微型超声可能会简化并优化这一流程。
OPTIMUM是一项三臂随机对照试验,比较微型超声引导活检与MRI/US融合以及MRI/微型超声“无轮廓”融合。该试验将研究单独使用微型超声或与mpMRI联合使用时,在前列腺活检过程中对初诊受试者检测临床显著性前列腺癌(csPCa)是否能提供有效指导。将有1200名受试者被随机分组。将评估其经济影响。
将比较每组中csPCa(定义为2级及以上分级组)的发生率。主要假设是MRI/US融合组与仅微型超声组(包括MRI/微型超声组中仅微型超声的盲法部分)之间csPCa发生率无劣效性。作为次要目标,还将比较MRI/微型超声融合组与MRI/US融合组之间的csPCa发生率。其他次要目标包括每种样本类型(mpMRI靶向、微型超声靶向、系统性)导致的csPCa诊断患者比例的增加、每种成像模式的阴性预测值,以及每组操作的卫生经济学分析。
OPTIMUM将确定微型超声是否可作为MRI/US融合活检的替代方法。该试验还将评估简化的“无轮廓”MRI/微型超声融合程序的疗效。采用微型超声技术将增加能够从以现代成像为中心的诊断策略中受益的男性比例,并可能有助于减少诊断流程中的变异性、复杂性、等待时间和成本。